June 8, 2020

Edwards Sapien 3 Transcatheter Heart Valve Approved in China

June 8, 2020—Edwards Lifesciences Corporation announced that it has received regulatory approval from China's National Medical Products Administration for the Sapien 3 transcatheter heart valve for the treatment of patients with severe, symptomatic aortic stenosis (AS) at high risk for or unable to undergo open-heart surgery. The valve is available in 20-, 23-, 26-, and 29-mm sizes.

The approval for high- and extreme-risk patients in China was supported by the Chinese SAPIEN 3 study, which complements clinical outcomes from three randomized controlled PARTNER studies as well as real-world results.

“Now, in China, patients diagnosed with severe AS have the option of a shorter procedure with excellent clinical outcomes, including a more rapid recovery than open heart surgery,” commented Professor Junbo Ge, MD, in the company's announcement. Professor Ge is academician of the Chinese Academy of Sciences; Chairman, Shanghai Institute of Cardiovascular Diseases; and Director, Department of Cardiology, Zhongshan Hospital, Fudan University in Shanghai, China.


June 9, 2020

Blue Sail Medical Acquires NVT

June 5, 2020

Baylor Study Recommends TEG Tests to Identify Clot Risk in ICU Patients With COVID-19